{"filing":{"accession_number":"0001628280-26-063875","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-09-29","report_date":"2026-09-30","primary_document":"telix-6kbipassgainsfdafast.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026063875/telix-6kbipassgainsfdafast.htm"},"events":[{"id":35873,"run_id":33059,"accession_number":"0001628280-26-063875","anchor_item_number":"EX-99","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The announcement discloses FDA Fast Track designation for Telix's BiPASS program, a clinical development milestone for a proprietary 68Ga-PSMA-PET imaging program in pre-biopsy prostate cancer diagnosis. Fast Track status facilitates more frequent FDA engagement and may enable expedited review of the planned NDA, representing a material regulatory advancement that would affect investor assessment of the company's development timeline and commercial prospects. This is an operational/regulatory milestone rather than a discrete event type (not an earnings release, M\u0026A activity, executive change, or financial obligation).","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-09-29","form":"6-K","submitted_at":null,"items":[{"id":40083,"accession_number":"0001628280-26-063875","item_number":"EX-99","item_title":"a20260930bipassftvfinala.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The announcement discloses FDA Fast Track designation for Telix's BiPASS program, a clinical development milestone for a proprietary 68Ga-PSMA-PET imaging program in pre-biopsy prostate cancer diagnosis. Fast Track status facilitates more frequent FDA engagement and may enable expedited review of the planned NDA, representing a material regulatory advancement that would affect investor assessment of the company's development timeline and commercial prospects. This is an operational/regulatory milestone rather than a discrete event type (not an earnings release, M\u0026A activity, executive change, or financial obligation).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:04:38.188973+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40083,"accession_number":"0001628280-26-063875","item_number":"EX-99","item_title":"a20260930bipassftvfinala.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The announcement discloses FDA Fast Track designation for Telix's BiPASS program, a clinical development milestone for a proprietary 68Ga-PSMA-PET imaging program in pre-biopsy prostate cancer diagnosis. Fast Track status facilitates more frequent FDA engagement and may enable expedited review of the planned NDA, representing a material regulatory advancement that would affect investor assessment of the company's development timeline and commercial prospects. This is an operational/regulatory milestone rather than a discrete event type (not an earnings release, M\u0026A activity, executive change, or financial obligation).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:04:38.188973+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-09-29"}]}